The University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
School of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.
Eur Radiol. 2024 Nov;34(11):7041-7052. doi: 10.1007/s00330-024-10816-2. Epub 2024 Jun 4.
To assess the diagnostic performance of post-contrast CT for predicting moderate hepatic steatosis in an older adult cohort undergoing a uniform CT protocol, utilizing hepatic and splenic attenuation values.
A total of 1676 adults (mean age, 68.4 ± 10.2 years; 1045M/631F) underwent a CT urothelial protocol that included unenhanced, portal venous, and 10-min delayed phases through the liver and spleen. Automated hepatosplenic segmentation for attenuation values (in HU) was performed using a validated deep-learning tool. Unenhanced liver attenuation < 40.0 HU, corresponding to > 15% MRI-based proton density fat, served as the reference standard for moderate steatosis.
The prevalence of moderate or severe steatosis was 12.9% (216/1676). The diagnostic performance of portal venous liver HU in predicting moderate hepatic steatosis (AUROC = 0.943) was significantly better than the liver-spleen HU difference (AUROC = 0.814) (p < 0.001). Portal venous phase liver thresholds of 80 and 90 HU had a sensitivity/specificity for moderate steatosis of 85.6%/89.6%, and 94.9%/74.7%, respectively, whereas a liver-spleen difference of -40 HU and -10 HU had a sensitivity/specificity of 43.5%/90.0% and 92.1%/52.5%, respectively. Furthermore, livers with moderate-severe steatosis demonstrated significantly less post-contrast enhancement (mean, 35.7 HU vs 47.3 HU; p < 0.001).
Moderate steatosis can be reliably diagnosed on standard portal venous phase CT using liver attenuation values alone. Consideration of splenic attenuation appears to add little value. Moderate steatosis not only has intrinsically lower pre-contrast liver attenuation values (< 40 HU), but also enhances less, typically resulting in post-contrast liver attenuation values of 80 HU or less.
Moderate steatosis can be reliably diagnosed on post-contrast CT using liver attenuation values alone. Livers with at least moderate steatosis enhance less than those with mild or no steatosis, which combines with the lower intrinsic attenuation to improve detection.
The liver-spleen attenuation difference is frequently utilized in routine practice but appears to have performance limitations. The liver-spleen attenuation difference is less effective than liver attenuation for moderate steatosis. Moderate and severe steatosis can be identified on standard portal venous phase CT using liver attenuation alone.
在接受统一 CT 方案的老年队列中,利用肝脏和脾脏衰减值评估对比后 CT 预测中度肝脂肪变性的诊断性能。
共有 1676 名成年人(平均年龄 68.4±10.2 岁;1045 名男性/631 名女性)接受了 CT 尿路上皮方案检查,包括平扫、门静脉期和肝脏及脾脏 10 分钟延迟期。使用经过验证的深度学习工具对衰减值(HU)进行自动肝脾分割。未增强肝脏衰减值<40.0 HU,对应>15%的基于 MRI 的质子密度脂肪,作为中度脂肪变性的参考标准。
中度或重度脂肪变性的患病率为 12.9%(216/1676)。门静脉期肝脏 HU 预测中度肝脂肪变性的诊断性能(AUROC=0.943)明显优于肝脏-脾脏 HU 差值(AUROC=0.814)(p<0.001)。门静脉期肝脏阈值为 80 和 90 HU 时,对中度脂肪变性的敏感性/特异性分别为 85.6%/89.6%和 94.9%/74.7%,而肝脏-脾脏差值为-40 HU 和-10 HU 时,敏感性/特异性分别为 43.5%/90.0%和 92.1%/52.5%。此外,中重度脂肪变性的肝脏显示出明显较低的对比后增强(平均,35.7 HU 比 47.3 HU;p<0.001)。
仅使用肝脏衰减值即可在标准门静脉期 CT 上可靠诊断中度脂肪变性。考虑脾脏衰减似乎没有什么价值。中度脂肪变性不仅固有地具有较低的平扫肝脏衰减值(<40 HU),而且增强程度也较低,通常导致增强后肝脏衰减值为 80 HU 或更低。
仅使用肝脏衰减值即可在增强 CT 上可靠诊断中度脂肪变性。至少中度脂肪变性的肝脏增强程度低于轻度或无脂肪变性的肝脏,这与较低的固有衰减相结合,提高了检测的准确性。
肝脏-脾脏衰减差值在常规实践中经常使用,但似乎存在性能限制。肝脏-脾脏衰减差值在中度脂肪变性中的效果不如肝脏衰减值。仅使用肝脏衰减值即可在标准门静脉期 CT 上识别中度和重度脂肪变性。